InvestorsHub Logo
Followers 30
Posts 2774
Boards Moderated 4
Alias Born 10/24/2015

Re: jondoeuk post# 120

Sunday, 03/20/2022 8:46:23 PM

Sunday, March 20, 2022 8:46:23 PM

Post# of 676
Additional immune checkpoint targets, cytokine tethered TIL, as well as transient and stable gene insertion and inactivation are being developed. Also, PD-1+ selected TIL (in a trial), CD39/69 double negative TIL [1], Gen 3 (16 day) manufacturing (in a trial), core biopsy (in a trial) [2] and an IL-2 analog.

Refs:
1 https://www.iovance.com/wp-content/uploads/Iovance_ESMO-IO-2021_AKTi-TIL-Expansion.pdf
2 https://www.iovance.com/wp-content/uploads/Iovance_SITC2019_Poster_Core_20191102_FINAL_DE.pdf

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IOVA News